|Bid||0.1700 x N/A|
|Ask||0.1800 x N/A|
|Day's Range||0.1700 - 0.1750|
|52 Week Range||0.0650 - 0.2000|
|Beta (5Y Monthly)||1.10|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr. 23, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Pascal Biosciences Inc. (TSX.V:PAS) ("Pascal") has entered into a Term Sheet with SōRSE Technology ("SōRSE") to develop Pascal’s cannabinoid programs. Investing in and financially supporting Pascal Biosciences’ research marks the first step for SōRSE Technology moving into medical research applications. This partnership leverages SōRSE’s industry-leading formulation technology with Pascal’s cannabinoid programs for clinical trials, led by Patrick Gray and his team of world-class medical researchers.
In exchange for the exclusive right to negotiate a definitive agreement, SōRSE has agreed to purchase units of Pascal, each unit consisting of one share and one warrant of Pascal, for gross proceeds of US$250,000 on a private placement basis (the "Private Placement"). Pascal intends to use the proceeds of the Private Placement for working capital purposes.
Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) and Y-Biologics (together the “Companies”) today announced a research collaboration agreement for the discovery and development of novel bispecific antibodies for the treatment of leukemia. Under the terms of the agreement, Y-Biologics will contribute its novel bispecific antibody platform technology, ALiCE, and Pascal will utilize its proprietary antibodies.
Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”) today revealed the mechanism whereby cannabinoids may directly aid in cancer treatment. Specific cannabinoids identified by Pascal scientists enhance the immunogenicity of tumour cells, rendering them more susceptible to recognition and elimination by the immune system.
Pascal announces that Dr. Patrick Gray, CEO, will present an update today on the Company’s lead cannabinoid-based drug candidate, PAS-403, at the Second Annual International Cannabinoid Derived Pharmaceuticals Summit taking place in Boston, MA. The Second Annual International Cannabinoid Pharmaceutical Conference brings together world leaders researching the discovery and development of drugs from cannabis. Dr. Gray will discuss PAS-403 for the treatment of glioblastoma, including the progression to preclinical development, development of a manufacturing process, and fulfillment of FDA-required studies for biochemistry, metabolism, and safety.